Norwegian Cruise Line Holdings Ltd vs Pfizer Inc — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $18.9 (market cap $8.59B), while Pfizer Inc trades at $26.3 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 17.7× Norwegian Cruise Line Holdings Ltd's market cap, and Pfizer Inc pays a 6.46% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals.
| NCLH | PFE | |
|---|---|---|
Market Cap | $8.59B | $151.73B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.94 | $28.56 |
52-Week Low | $14.79 | $23.60 |
Enterprise Value | $23.40B | $203.22B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.46% |
Signals from Pluang's Aura AI — not financial advice
NCLH trades at $19.09, up 2.91% today, with a bearish technical signal but recent earnings beats. The company reported Q2 2026 EPS of $0.48, exceeding the $0.4115 estimate, and revenue growth has improved from $4.8B in 2022 to $9.83B in 2025. However, net income margin declined to 4.3% in 2025 from 9.6% in 2024, and high debt levels remain a concern with total liabilities of $18.54B against equity of $1.43B.
The outlook is mixed: analyst consensus is a Buy with a $20.73 price target, but risks include volatile fuel costs, macroeconomic pressures on travel demand, and execution of turnaround plans. The stock offers value with a P/E of 11.33, yet investor sentiment is cautious due to recent guidance cuts and bearish technical indicators.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Trailing returns across standard periods
Latest headlines on both assets
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →